Supply Chain Intelligence

Supernus Pharmaceuticals, Inc. Supply Chain

SUPN supply chain intelligence for Supernus Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

SUPN ·Last updated 2026-07-29 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

21Suppliers
26Customers
3Debt Items
20Related Chains

Supernus Pharmaceuticals, Inc. Suppliers

TickerNameConfidenceEvidence
BRITANNIA BRITANNIA 92% Per the Agreement, Britannia has an obligation to supply us with APOKYN for our marketing and sale of the product.
NAVITOR-PHARMACEUTICALS-INC NAVITOR-PHARMACEUTICALS-INC 92% Supernus Pharmaceuticals, Inc. entered into an Asset Purchase Agreement with Navitor Pharmaceuticals, Inc., a Delaware corporation, under which the Company agreed to acquire from the Sellers all of t…
NAVITOR-PHARMACEUTICALS-LLC NAVITOR-PHARMACEUTICALS-LLC 92% Supernus Pharmaceuticals, Inc. entered into an Asset Purchase Agreement with Navitor Pharmaceuticals, LLC, a Delaware limited liability company, together with related ancillary transaction documents,…
ZAMBON ZAMBON 92% Under the Supply Agreement, we must purchase from Zambon and Zambon must provide to us all XADAGO finished products for the U.S. market.
APHENA-PHARMA-SOLUTIONS APHENA-PHARMA-SOLUTIONS 85% For Qelbree, Trokendi XR, GOCOVRI, and Oxtellar XR we currently rely on third-party CMOs for the manufacturing and packaging of final commercial products.
CATALENT-PHARMA-SOLUTIONS CATALENT-PHARMA-SOLUTIONS 85% For Qelbree, Trokendi XR, GOCOVRI, and Oxtellar XR we currently rely on third-party CMOs for the manufacturing and packaging of final commercial products.
PACKAGING-COORDINATORS-INC PACKAGING-COORDINATORS-INC 85% For Qelbree, Trokendi XR, GOCOVRI, and Oxtellar XR we currently rely on third-party CMOs for the manufacturing and packaging of final commercial products.
PATHEON-PHARMACEUTICALS-INC PATHEON-PHARMACEUTICALS-INC 85% For Qelbree, Trokendi XR, GOCOVRI, and Oxtellar XR we currently rely on third-party CMOs for the manufacturing and packaging of final commercial products.
CAH Cardinal Health, Inc. 72% Reciprocal relationship from CAH graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from CAH graph: Reciprocal relationship from SUPN graph: could be harmed. The majority of our …
CAH Cardinal Health, Inc. 72% could be harmed. The majority of our product sales are to pharmaceutical wholesalers, specialty pharmacies, and distributors who, in turn, sell our products to pharmacies, hospitals, and other custom…
MCK McKesson Corporation 72% could be harmed. The majority of our product sales are to pharmaceutical wholesalers, specialty pharmacies, and distributors who, in turn, sell our products to pharmacies, hospitals, and other custom…
MCK McKesson Corporation 72% Reciprocal relationship from MCK graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from MCK graph: Reciprocal relationship from SUPN graph: could be harmed. The majority of our …
ORANY ORANY 72% y to it, then the Company may be subject to penalties, both civil and criminal, damages, fines, exclusion from federal healthcare programs, and/or the curtailment or restructuring of its operations. …
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from SUPN graph: y to it, then the Company may be …
SGIOF Shionogi & Co., Ltd. 72% following promises in the Biogen Collaboration Agreement that were evaluated under the scope of ASC 606: delivery of (i) a co-exclusive license for SAGE-217 products in the U.S.; (ii) an exclusive li…
SGIOF Shionogi & Co., Ltd. 72% Reciprocal relationship from SGIOF graph: Reciprocal relationship from SUPN graph: following promises in the Biogen Collaboration Agreement that were evaluated under the scope of ASC 606: delivery of…
TKPHF Takeda Pharmaceutical Company Limited 72% cidental contamination or injury from these materials. In the event of an accident, local, city, state, or federal authorities may curtail the use of these materials and may interrupt our business op…
TKPHF Takeda Pharmaceutical Company Limited 72% Reciprocal relationship from TKPHF graph: Reciprocal relationship from SUPN graph: cidental contamination or injury from these materials. In the event of an accident, local, city, state, or federal a…
TMO Thermo Fisher Scientific Inc. 72% hat used in Phase 2 clinical trials, nor do we have plans to develop our own manufacturing operations in the foreseeable future to support Phase 3 clinical trials or commercial production. We current…
TMO Thermo Fisher Scientific Inc. 72% Reciprocal relationship from TMO graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from TMO graph: Reciprocal relationship from SUPN graph: hat used in Phase 2 clinical trials, …
ZVRA Zevra Therapeutics, Inc. 72% Reciprocal relationship from ZVRA graph: eparation. UCDs are a group of rare genetic disorders that can cause harmful ammonia to build up in the blood, potentially resulting in brain damage and neuro…

Supernus Pharmaceuticals, Inc. Customers

TickerNameConfidenceEvidence
BIOGEN BIOGEN 92% The Company has a collaboration agreement with Biogen (Biogen Collaboration Agreement) for the co-commercialization of ZURZUVAE in the U.S.
CAH Cardinal Health, Inc. 72% Reciprocal relationship from CAH graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from CAH graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from CAH grap…
CAH Cardinal Health, Inc. 72% could be harmed. The majority of our product sales are to pharmaceutical wholesalers, specialty pharmacies, and distributors who, in turn, sell our products to pharmacies, hospitals, and other custom…
MCK McKesson Corporation 72% Reciprocal relationship from MCK graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from MCK graph: Reciprocal relationship from SUPN graph: could be harmed. The majority of our …
MCK McKesson Corporation 72% could be harmed. The majority of our product sales are to pharmaceutical wholesalers, specialty pharmacies, and distributors who, in turn, sell our products to pharmacies, hospitals, and other custom…
RAPP Rapport Therapeutics, Inc. 72% Reciprocal relationship from RAPP graph: into longer-term commercial supply agreements to fulfill and secure our production needs. While the drug substances used in our product candidates are manufac…
SGIOF Shionogi & Co., Ltd. 72% . • Shionogi - The Company also has a collaboration agreement with Shionogi & Co., Ltd. (Shionogi) (Shionogi Collaboration Agreement) whereby the Company is entitled to receive royalties and mileston…
SGIOF Shionogi & Co., Ltd. 72% Reciprocal relationship from SGIOF graph: Reciprocal relationship from SUPN graph: . • Shionogi - The Company also has a collaboration agreement with Shionogi & Co., Ltd. (Shionogi) (Shionogi Collabo…
TKPHF Takeda Pharmaceutical Company Limited 72% cidental contamination or injury from these materials. In the event of an accident, local, city, state, or federal authorities may curtail the use of these materials and may interrupt our business op…
TKPHF Takeda Pharmaceutical Company Limited 72% Reciprocal relationship from TKPHF graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from SUPN graph: cidental contamination or injury …
TMO Thermo Fisher Scientific Inc. 72% Reciprocal relationship from TMO graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from TMO graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from TMO grap…
TMO Thermo Fisher Scientific Inc. 72% d other specialized health care providers in the U.S. in the Parkinson's area. Another sales force focuses on psychiatrists, pediatricians, primary care physicians, and advanced practice providers in…
UTHR United Therapeutics Corporation 72% Reciprocal relationship from UTHR graph: Reciprocal relationship from SUPN graph: .e., at the time of sale to wholesalers/distributors). This liability is recorded as a reduction to gross product sal…
UTHR United Therapeutics Corporation 72% .e., at the time of sale to wholesalers/distributors). This liability is recorded as a reduction to gross product sales, and an increase in Accrued product returns and rebates. The liability is recor…
XENE Xenon Pharmaceuticals Inc. 72% Reciprocal relationship from XENE graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from XENE graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from XENE g…
ZVRA Zevra Therapeutics, Inc. 72% Reciprocal relationship from ZVRA graph: eparation. UCDs are a group of rare genetic disorders that can cause harmful ammonia to build up in the blood, potentially resulting in brain damage and neuro…
ACORDA-THERAPEUTICS-INC ACORDA-THERAPEUTICS-INC 62% f our major products were to become subject to problems, such as changes in prescription growth rates, unexpected side effects, loss of intellectual property protection, supply chain or product suppl…
CENCORA-INC-CARDINAL-HEALTH-INC CENCORA-INC-CARDINAL-HEALTH-INC 62% ounts, our business could be harmed. The majority of our product sales are to pharmaceutical wholesalers, specialty pharmacies, and distributors who, in turn, sell our products to pharmacies, hospita…
ELAN-PHARMACEUTICALS-LLC ELAN-PHARMACEUTICALS-LLC 62% ear term of the agreement is subject to automatic renewal periods unless canceled by either party. Either party may terminate the agreement under certain circumstances, including a material breach of…
MERZ-PHARMACEUTICALS-LLC MERZ-PHARMACEUTICALS-LLC 62% f our major products were to become subject to problems, such as changes in prescription growth rates, unexpected side effects, loss of intellectual property protection, supply chain or product suppl…
MERZ-PHARMA-GMBH MERZ-PHARMA-GMBH 62% ear term of the agreement is subject to automatic renewal periods unless canceled by either party. Either party may terminate the agreement under certain circumstances, including a material breach of…
NAVITOR-PHARMACEUTICALS-INC NAVITOR-PHARMACEUTICALS-INC 62% of discontinuance to withdraw Osmolex ER from distribution. Distribution of Osmolex ER ceased on April 1, 2024. The Company recognized noncash royalty revenues of $ 4.0 million, and $ 9.8 million for…
NAVITOR-PHARMACEUTICS-LLC NAVITOR-PHARMACEUTICS-LLC 62% red to purchase a minimum quantity of finished products on an annual basis. This minimum purchase requirement represents the in-substance fixed contract consideration associated with the dedicated ma…
PATHEON-PHARMACEUTICALS-INC PATHEON-PHARMACEUTICALS-INC 62% the U.S. are effectively targeting healthcare providers to support and grow our key commercial products. One sales force focuses on serving movement disorder specialists and other specialized health …
STADA-ARZNEIMITTEL-AG STADA-ARZNEIMITTEL-AG 62% the U.S. are effectively targeting healthcare providers to support and grow our key commercial products. One sales force focuses on serving movement disorder specialists and other specialized health …
SUNOVION-PHARMACEUTICALS-INC SUNOVION-PHARMACEUTICALS-INC 62% f our major products were to become subject to problems, such as changes in prescription growth rates, unexpected side effects, loss of intellectual property protection, supply chain or product suppl…

Supernus Pharmaceuticals, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
SUPN-DEBT-12821 Warrants outstanding: 80.91 90% xbrl warrant detail from xbrl 2023-12-31.
SUPN-DEBT-12822 Xbrl Convertible 90% xbrl convertible detail from xbrl 2022-12-31.
SUPN-DEBT Debt stack $40.9M 90% Market cache reports total debt of $40.9M.

Supernus Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Supernus Pharmaceuticals, Inc..

Supernus Pharmaceuticals, Inc. Ownership

HolderNameConfidenceEvidence
SUPN-OWNER-BLACKROCK-INC BlackRock, Inc. 90% 13F overlay lists BlackRock, Inc. as top holder; 331 tracked holders.

Supernus Pharmaceuticals, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
HLNCF Haleon plc 100.00 2
GH Guardant Health, Inc. 100.00 2
CLH Clean Harbors, Inc. 100.00 2
CLLS Cellectis S.A. 100.00 2
HALO Halozyme Therapeutics, Inc. 100.00 2
HLN Haleon plc 100.00 2
REGN Regeneron Pharmaceuticals, Inc. 100.00 2
CAH Cardinal Health, Inc. 100.00 1 ['customer', 'supplier']
ARDX Ardelyx, Inc. 100.00 2
BHPLF BHP Group Limited 100.00 2
GILD Gilead Sciences, Inc. 100.00 2
ICLR ICON Public Limited Company 100.00 2
CVS CVS Health Corporation 100.00 2
GRDN Guardian Pharmacy Services, Inc. 100.00 2
EMMA Emmaus Life Sciences, Inc. 100.00 2
CHRS Coherus Oncology, Inc. 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
ORANY ORANGE 100.00 1 ['supplier']
BTAI BioXcel Therapeutics, Inc. 100.00 2
IDXG Interpace Biosciences, Inc. 100.00 2

Explore the full interactive supply chain map for Supernus Pharmaceuticals, Inc..

Open SUPN supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map